FDA Fast Track designation for pelareorep in anal cancer
Oncolytics Biotech received FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.
The designation follows results already presented from the GOBLET study, which showed signs of improved outcomes versus historical experience in this setting.
Fast Track status supports a potential registrational pathway, including more frequent FDA engagement and a possible rolling BLA review.
The company framed the opportunity as an estimated nearly USD 1 billion U.S. market with no FDA-approved options post first-line standard of care.
This is pelareorep’s third FDA Fast Track designation in gastrointestinal cancers, adding regulatory momentum across its pipeline.
ONCY•
